Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics is using equity inducement grants to attract six new hires, with options and RSUs vesting over four years.
Rhea-AI Summary
Vera Therapeutics (VERA) granted inducement equity awards on September 1, 2026 to six new employees under its 2024 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The grants include non-qualified stock options to purchase 61,500 Class A shares at an exercise price of $34.23 per share and RSUs covering 30,750 Class A shares. Options vest over four years, with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually over four years from either August 20 or November 20, 2026, depending on employee start date, subject to continued service.
Positive
- Equity awards to six new hires may aid recruitment and retention
- Vesting over four years aligns employee incentives with longer-term shareholder value
Negative
- 92,250 new equity awards (options plus RSUs) add future dilution for existing shareholders
- Stock-based compensation at a $34.23 option strike may increase ongoing compensation expense
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 01 | Investor conference notice | Neutral | +0.5% | Announced participation in two upcoming healthcare investor conferences. |
| Aug 10 | Second-quarter earnings | Positive | -4.0% | Reported accelerated approval and commercial launch alongside quarterly financial results. |
| Aug 07 | Inducement equity grants | Negative | -4.0% | Granted options and RSUs to new regulatory leadership and employees. |
| Jul 10 | Inducement equity grants | Negative | -1.2% | Granted options and RSUs to eight new employees. |
| Jul 09 | Leadership transition | Neutral | +0.1% | Announced chief regulatory officer succession and planned retirement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable inducement-grant announcements were followed by negative 24-hour price reactions, while the recent earnings update also declined despite a regulatory milestone.
Key Terms
non-qualified stock options financial
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on September 1, 2026 has an exercise price per share equal to
About Vera Therapeutics
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNATM (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
FAQ
What equity inducement grants did Vera Therapeutics (VERA) announce on September 4, 2026?
Vera Therapeutics announced inducement equity awards granted on September 1, 2026 to six new employees, consisting of non-qualified stock options for 61,500 Class A shares and RSUs covering 30,750 Class A shares under its 2024 Inducement Plan.
What is the exercise price of the new Vera Therapeutics (VERA) stock options?
Each non-qualified stock option granted on September 1, 2026 has an exercise price of $34.23 per share, equal to Vera Therapeutics’ closing trading price on that date.
How do the Vera Therapeutics (VERA) inducement stock options vest?
The stock options vest over four years. 25% of the underlying shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, subject to continued service.
What is the vesting schedule for the RSUs in the Vera Therapeutics (VERA) inducement grants?
Each RSU award vests over four years, with 25% of the underlying shares vesting on each anniversary of either August 20 or November 20, 2026, depending on the employee’s start date, subject to continued service.
Under which plan were the Vera Therapeutics (VERA) inducement awards granted?
The inducement stock options and RSUs were granted under the Vera Therapeutics 2024 Inducement Plan, with each award also governed by a specific award agreement.
Why were the Vera Therapeutics (VERA) inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?
The Compensation Committee approved these equity awards as an inducement material to the new employees’ employment, in accordance with Nasdaq Listing Rule 5635(c)(4), which permits inducement grants without prior shareholder approval under specified conditions.